Immuron (ASX:IMC) said fiscal 2025 sales are "on track" to exceed AU$7 million, up from AU$4.9 million a year earlier, according to a May 30 filing with the Australian bourse.
All of the US armed services participants in the field study for Travelan, the company's therapy candidate for traveler's diarrhea, have been deployed, the filing said.
The biopharmaceutical firm expects the final visit of the last patient in July, with results slated for release in October, the filing added.
The company also expects an investigational new drug submission for IMM-529, a drug candidate for colon infection, to the US Food and Drug Administration in August.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。